The current work focuses on the study of polymeric, biodegradable nanoparticles (NPs) for the encapsulation of doxorubicin and mitomycin C (anti-leishmanial drugs), and their efficient delivery to macrophages, the parasite's home. The biodegradable polymer methoxypoly-(ethylene glycol)-b-poly (lactic acid) (MPEG-PLA) was used to prepare polymeric NPs encapsulating doxorubicin and mitomycin C. The morphology, mean diameter, and surface area of spherical NPs were determined by transmission electron microscopy (TEM), field emission scanning electron microscopy (FESEM), and BET surface area analysis. X-ray diffraction was performed to validate drug encapsulation. An in vitro release profile of the drugs suggested a fairly slow release. These polymeric NPs were efficiently capable of releasing drug inside macrophages at a slower pace than the free drug, which was monitored by epi-fluorescence microscopy. Encapsulation of doxorubicin and mitomycin C into NPs also decreases cellular toxicity in mouse macrophages (J774.1A).
Get full access to this article
View all access options for this article.
References
1.
BallyMB, LimH, CullisPRet al.Controlling the drug delivery attributes of lipid- based drug formulations. J Liposome Res, 1998; 8:299–335.
2.
BriggerI, DubernetC, CouvreurP. NPs in cancer therapy and diagnosis. Adv Drug Deliv Rev, 2002; 54:631–651.
3.
ChengJ, TeplyBA, SherifiIet al.Formulation of functionalized PLGA-PEG NPs for in vivo targeted drug delivery. Biomaterials, 2007; 28:869–876.
4.
DesaiMP, LabhasetwarV, WalterEet al.The mechanism of uptake of biodegradable microparticles in CaCO-2 cells is size dependent. Pharm Res, 1997; 14:1568–1573.
5.
DesjeuxP. Human leishmaniases: epidemiology and public health aspects. World Health Stat, 1992; 45:267–275.
6.
DirixLY, LiburaM, LiburaJet al.In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anti-Cancer Drugs, 1997; 8:859–868.
7.
DongY, FengSS. Methoxy poly (ethylene glycol)-poly (lactide) (MPEG-PLA) NPs for controlled delivery of anticancer drug. Biomaterials, 2004; 25:2843–2849.
8.
FessiH, PuisieuxF, DevissaguetJPet al.Nanocapsules formation by interfacial polymer deposition following solvent displacement. Int J Pharm, 1989; 55:25–28.
9.
FrankG, LangerR, FarokhzadOC. Precise engineering of targeted NPs by using self assembled biointegrated block copolymers. PNAS, 2008; 105:2586.
10.
GordonS. The macrophage. BioEssays, 1995; 17:977–986.
11.
GrefR, DombA, QuellecPet al.The controlled intravenous delivery of drugs using PEG-ciated sterically stabilized nanospheres. Adv Drug Deliv Rev, 1995; 16:215–233.
12.
GuptaS, PalA, VyasSP. Drug delivery strategies for therapy of visceral leishmaniasis. Expert Opin Drug Deliv, 2010; 7:371–402.
13.
JonesMC, LerouxJC. Polymeric micelle—a new generation of colloidal drug carriers. Eur J Pharm Biopharm, 1995; 48:101–111.
LundbergB, GriffithsG, HansenHJ. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. J Control Rel, 2004; 94:155–161.
16.
McLennanIJ, LenkinskiRE, YanukaY. A nuclear magnetic resonance study of the self association of adriamycin and daunomycin in aqueous solution. Can J Chem, 1985; 63:1233–1238.
17.
MenozziM, ValentiniL, VanniniEet al.Self association of doxorubicin and related compounds in aqueous solution. J Pharm Sci, 1984; 73:766–770.
18.
MosmannT. Rapid colorimetric assay for cellular growth and survival, application to proliferation and cytotoxicity assays. J Immunol Methods, 1983; 65:55–63.
19.
MurielP, AbdelkaderL, HatemFet al.Pentamidine loaded poly (D, L-lactide) NPs: adsorption and drug release. Drug Dev Res, 1998; 43:98–104.
20.
MylerP, FaselN. Leishmania: after the genome. Norfolk: Caister Academic, 2008.
21.
OfecI, GoldharJ, KeisariYet al.Nonopsonic phagocytosis of microorganisms. Annu Rev Microbiol, 1995; 49:239–276.
22.
PanyamJ, LabhasetwarV. Biodegradable NPs for drug and gene delivery to cells and tissues. Adv Drug Deliv Rev, 2003; 55:329–347.
23.
RighettiPG. Charge-state and charge-continuum models in electrophoresis and isoelectric focusing of genetic variants. J Chromatogr, 1979; 173:1–5.
24.
ServiceRF. Nanotechnology takes aim at cancer. Science, 2005; 310:1132–1134.
25.
SettR, BasuN, GhoshAK, DasPK. Potential of doxorubicin as an antilieshmanial agent. J Parasitol, 1992; 78:350–354.
26.
ShuklaAK, PatraS, DubeyVK. Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative chemotherapy of leishmaniasis. Mol Cell Biochem, 2011; 352:261–270.
27.
ShuklaAK, SinghBK, PatraSet al.Rational approaches for drug designing against leishmaniasis. Appl Biochem Biotechnol, 2010; 160:2208–2218.
28.
TardiPG, BomanNL, CullisPR. Liposomal doxorubicin. J Drug Target, 1996; 4:129–140.
29.
TorchilinnVP, TrubetskoyVS. Which polymers can make nanoparticulate drug carriers long- circulating?Adv Drug Deliv Rev, 1995; 16:141–155.
30.
XiaoRZ, ZengZW, ZhouGLet al.Recent advances in PEG-PLA block copolymer NPs. Int J Nanomedicine, 2010; 5:1057–1065.
31.
YiY, KimJH, KangHWet al.A polymeric NP consisting of mPEG- PLA-Toco and PLMA-COONa as a drug carrier: Improvements in cellular uptake and biodistribution. Pharma Res, 2005; 22:200–208.
32.
YokoyamaM, FukushimaS, UcharaRet al.Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J Contol Rel, 1998; 50:79–92.
33.
ZhengX, KanB, GouMet al.Preparation of MPEG-PLA NP for honokiol delivery in vitro. Int J Pharm, 2010; 386:262–267.
